Live biotherapeutic products: the importance of a defined regulatory framework
Prevention and treatment: When living microbes become medicines Regulatory frameworks must be stretched to include microbe-based medicines such as “live biotherapeutic products” (LBPs). Some LBPs are similar by nature to probiotics, health-enhancing living microbes, except that they are meant to tre...
Main Authors: | Magali Cordaillat-Simmons, Alice Rouanet, Bruno Pot |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-09-01
|
Series: | Experimental and Molecular Medicine |
Online Access: | https://doi.org/10.1038/s12276-020-0437-6 |
Similar Items
-
Factors that influence clinical efficacy of live biotherapeutic products
by: Bruno Pot, et al.
Published: (2021-05-01) -
Entering First-in-Human Clinical Study With a Single-Strain Live Biotherapeutic Product: Input and Feedback Gained From the EMA and the FDA
by: Jeanne-Céleste Paquet, et al.
Published: (2021-08-01) -
Live Biotherapeutic Products, A Road Map for Safety Assessment
by: Alice Rouanet, et al.
Published: (2020-06-01) -
Regulatory Pathway for Licensing Biotherapeutics in Mexico
by: Carlos A. López-Morales, et al.
Published: (2018-09-01) -
Asymptomatic bacteriuria Escherichia coli are live biotherapeutics for UTI.
by: Charles N Rudick, et al.
Published: (2014-01-01)